Introduction

Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%. A single patient case illustrates both how quickly this syndrome can escalate and how far second-line immunosuppression strategies have evolved for managing it.

Case Presentation

An 80-year-old male with stage III clear cell renal cell carcinoma underwent right radical nephrectomy, then began adjuvant pembrolizumab 200 mg IV every 3 weeks. Cycle 2 was deferred one week for elevated liver function tests and fatigue. He presented to the emergency department with generalized weakness, fatigue, and elevated liver function tests; labs drawn for the fatigue workup revealed transaminitis and elevated creatine kinase, raising concern for immune-related toxicity. Methylprednisolone 1 mg/kg/day (100 mg) was initiated, with troponin elevated at 916.4 ng/L.

Neurology exam found right ptosis, mild proximal weakness, and mild bulbar weakness, with a single breath count of 36 and sustained upward gaze for 60-plus seconds; monitoring included maximal expiratory pressure and negative inspiratory force every 6 hours for 24 hours, then every 12 hours. Acetylcholine receptor binding antibody returned positive (0.29 nmol/L; normal less than 0.02), though modulating flow cytometry was negative. A negative flow cytometry result does not rule out ICI-related myasthenia gravis. MRI of the bilateral thighs showed findings most consistent with bilateral myositis, predominantly involving the right side. Cardiac workup showed elevated troponin, an echocardiogram with LVEF 63% and mild dilation of the ascending aorta and dilated IVC, and cardiac MRI impression of a small subtle area of heterogeneous late gadolinium enhancement along the basal lateral wall with subtle increased T1 and T2 values in the same region, which could represent myocarditis given the clinical history.

Triple M Syndrome: Recognition and Initial Management

Triple M syndrome has a low incidence, under 1%, of immune checkpoint inhibitor-related toxicity, but a poor prognosis with fatality rates around 40%, and early recognition and initiation of treatment is important. NCCN guidelines provide system-specific assessment and management recommendations for immune-related adverse events including myocarditis, myasthenia gravis, and myositis, but there remains a lack of consensus guidance for managing overlap syndromes specifically.

General recommendations across all three systems: discontinue or hold the ICI, evaluate for concomitant involvement of the other two conditions, and initiate high-dose corticosteroids, with escalation to immunosuppression if steroid-refractory. For myasthenia gravis specifically, NCCN recommends acetylcholine receptor antibody testing, pulmonary function assessment (including strength testing), and considering an inpatient neurology consult. For myocarditis, cardiology consult, telemetry, EKG, echocardiogram, cardiac biomarkers (troponin, BNP or NT-proBNP), and cardiac MRI are recommended.

Given the multi-system involvement and abnormal cardiac imaging, methylprednisolone was increased to ICI-myocarditis dosing (1000 mg IV daily x 5 days).

When Steroids Aren't Enough: The ATRIUM Trial and Abatacept

If a patient improves within 24–48 hours of steroid initiation, steroids are continued with a taper over 6–12 weeks based on clinical response. If there is no improvement within 24–48 hours, second-line immunosuppression is warranted, with options including abatacept, alemtuzumab, antithymocyte globulin, infliximab, IVIG, methotrexate, mycophenolate mofetil, or plasmapheresis, chosen based on concomitant conditions or other patient factors.

Abatacept is a CTLA-4 fusion protein that blocks CD28-CD80/CD86 costimulatory signaling, directly counteracting the mechanism by which checkpoint inhibitors work in the first place and restoring immune checkpoint regulation. It requires a minimum of two weeks to see a response and up to ten weeks to achieve peak blockade. The ATRIUM trial (Abatacept for Immune Checkpoint Inhibitor-Associated Myocarditis), a phase 3, investigator-initiated, randomized, double-blind, placebo-controlled study (NCT05335928), enrolls patients 18 years or older with ICI-related myocarditis, serum evidence of ongoing myocardial injury (troponin ≥5x the upper limit of normal), already treated with 1000 mg methylprednisolone per day, and randomizes them to abatacept 10 mg/kg IV or placebo.

Adding Ruxolitinib: Rationale for Combination Therapy

Ruxolitinib, a JAK1/JAK2 inhibitor, reduces cytokine signaling across the interferon, TNF, and IL-1/IL-6/IL-18 pathways, suppressing the inflammatory cascade; it takes only a few hours to achieve peak blockade, which is considerably faster than abatacept. The rationale for combining the two: target upstream and downstream immune activation simultaneously, reduce mortality, and improve ejection fraction recovery, since abatacept alone is slower to achieve control. Data suggest the combination of ruxolitinib and abatacept improved survival in patients with concurrent myositis.

Case Outcome and Practical Challenges

With combination abatacept and ruxolitinib, the patient’s cardiac biomarkers (troponin, pro-BNP) declined and he was ultimately discharged, continuing on a steroid taper and ruxolitinib with outpatient follow-up. His case also surfaced several practical, non-clinical challenges worth anticipating: abatacept and ruxolitinib administration require outpatient insurance prior authorization, raising questions of who manages this (cardio-oncology versus medical oncology) and how infusions get scheduled; ruxolitinib, while inpatient dosing is provided by the hospital, must be sent to a specialty pharmacy for outpatient prescriptions, and many insurance companies deny it as off-label use, making manufacturer patient assistance programs worth investigating in advance. GI and PJP prophylaxis (options include Bactrim, pentamidine, and atovaquone) added complexity given the patient's comorbidities, and guideline-directed medical therapy for his cardiac status including amiodarone plus apixaban for atrial fibrillation with rapid ventricular response.

A second trial, ACHYLS (Abatacept for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis, NCT05195645), is also ongoing: a phase 2, randomized, double-blind, dose-finding study testing abatacept at 10, 20, or 25 mg/kg IV on days 1, 5±2, and 14±2, combined with concomitant ruxolitinib and steroids in hospitalized patients with ICI myocarditis, with a primary endpoint of CD86 receptor occupancy of at least 80% on circulating monocytes, sustained through 3 weeks. ATRIUM's estimated completion is 2027; ACHYLS's is 2026.

For Patients

Triple M syndrome is a rare but potentially serious side effect of immunotherapy drugs called checkpoint inhibitors (commonly used for kidney cancer, melanoma, lung cancer, and others), involving inflammation of the heart muscle (myocarditis), a nerve-muscle condition causing weakness (myasthenia gravis), and muscle inflammation (myositis) occurring together. Symptoms can include fatigue, muscle weakness, drooping eyelids, and breathing or heart rhythm changes. If you're on a checkpoint inhibitor and develop new or worsening muscle weakness, unusual fatigue, or heart-related symptoms, contact your oncology team promptly, since early recognition and treatment meaningfully improve outcomes. Treatment typically starts with high-dose steroids, and newer medications, including one that blocks the same immune pathway the checkpoint inhibitor activated, are being studied specifically for cases that don't respond to steroids alone.

Key Takeaways

  • Triple M syndrome (myocarditis, myasthenia gravis, myositis) is rare (incidence under 1%) but carries a fatality rate around 40%; recognize and evaluate promptly for any new cardiac, neuromuscular, or respiratory symptoms in a patient on checkpoint inhibitor therapy.

  • A normal ejection fraction and normal cardiac MRI do not rule out ICI-related myocarditis; a negative myasthenia gravis flow cytometry result likewise does not rule out that diagnosis.

  • Treat early and aggressively: hold the ICI and initiate high-dose corticosteroids immediately, with rapid escalation to second-line immunosuppression (abatacept, with or without ruxolitinib) if no improvement within 24–48 hours.

  • Two ongoing randomized trials, ATRIUM and ACHYLS, are evaluating abatacept (with ACHYLS also incorporating ruxolitinib) specifically for ICI-related myocarditis, and the landscape of second-line immunosuppression for this syndrome continues to evolve.

  • Practical barriers, including insurance prior authorization and off-label specialty pharmacy access for abatacept and ruxolitinib, are common and worth anticipating early in a patient's hospitalization.

References

  1. Abatacept in Immune Checkpoint Inhibitor Myocarditis (ATRIUM). ClinicalTrials.gov. NCT05335928.

  2. Abatacept for the Treatment of Immune Checkpoint Inhibitors Induced Myocarditis (ACHYLS). ClinicalTrials.gov. NCT05195645.

  3. National Comprehensive Cancer Network. Management of Immunotherapy-Related Toxicities. Version 2.2026. Accessed June 2026.